t(9;21) Philadelphia chromosome
The Philadelphia chromosome results from a chromosomal translocation creating an oncogenic fusion. It is a defining feature in certain leukemias and guides targeted therapy.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where t(9;21) Philadelphia chromosome is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Chronic Myeloid Leukemia (CML) Heme · Leukemia |
|
Approvals defined at the solid tumor level where t(9;21) Philadelphia chromosome is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report t(9;21) Philadelphia chromosome as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports t(9;21) Philadelphia chromosome as part of its biomarker panel.